Skip to main content
Mark Ratain, MD, Oncology, Chicago, IL, University of Chicago Medical Center

MarkJRatainMD

Oncology Chicago, IL

Gastrointestinal Cancer, Hematologic Oncology

Leon O. Jacobson Professor of Medicine, The University of Chicago Medicine; Director, Center for Personalized Therapeutics; Associate Director for Clinical Sciences, Comprehensive Cancer Center

Overview of Dr. Ratain

Dr. Mark Ratain is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from Yale School of Medicine and has been in practice 37 years. Dr. Ratain accepts several types of health insurance, listed below. He is one of 118 doctors at University of Chicago Medical Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 1983 - 1986
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1980 - 1983
  • Yale School of Medicine
    Yale School of MedicineClass of 1980
  • Harvard University
    Harvard UniversityA.B., Biochemical Sciences, Magna cum Laude

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1983 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology
  • American Board of Clinical PharmacologyClinical Pharmacology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2014
  • Chicago Magazine: Top Doctors Castle Connolly, 2004, 2006, 2008, 2010, 2012, 2014
  • Spotlight on Science Featured Speaker American Society of Health System Pharmacists, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19  
    Mark J Ratain, Leonard B Saltz, JAMA Oncology
  • A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer Using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)  
    Hope S Rugo, Francisco Castillos, Beth Overmoyer, Mark J Ratain, Clinical Pharmacology & Therapeutics
  • A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469  
    Ramirez J, Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJ, Pharmacogenet Genomics, 1/1/2014
  • Join now to see all

Lectures

  • Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621. 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19May 2020

Press Mentions

  • A Group of Cancer Doctors Discovered a Way to Slash the Cost Expensive Pills by up to 75%, but They've Hit a Wall
    A Group of Cancer Doctors Discovered a Way to Slash the Cost Expensive Pills by up to 75%, but They've Hit a WallNovember 29th, 2017
  • FDA Rejects Eagle Pharma's Reformulated Angiomax
    FDA Rejects Eagle Pharma's Reformulated AngiomaxMarch 18th, 2016
  • Taking a Standard Prostate Cancer Drug with Food Boosts Impact, Lowers Cost
    Taking a Standard Prostate Cancer Drug with Food Boosts Impact, Lowers CostMarch 30th, 2018
  • Join now to see all

Grant Support

  • Phase I Clinical Trials Of Anti-Cancer AgentsNational Cancer Institute2003–2012
  • Parent Project - Main Theme (MAIN)National Institute Of General Medical Sciences2010–2011
  • Paar-Pharmacogenomics Of Anticancer Agents Research GroupNational Institute Of General Medical Sciences2010–2011
  • Core V - Liver Tissue Core (LTC)National Institute Of General Medical Sciences2010–2011
  • Core IV - Management And Administrative Core (MAC)National Institute Of General Medical Sciences2010–2011
  • Clinical TherapeuticsNational Institute Of General Medical Sciences1992–2011
  • Colorectal CancerNational Institute Of General Medical Sciences2005–2009
  • Pharmacogenetics Of Anticancer Agents Research GroupNational Institute Of General Medical Sciences2000–2009
  • Foreign Accrual For 5u10ca069852 - 2006 LoadNational Cancer Institute2006
  • Sorafenib(Bay43-9006) And Blood PressureNational Center For Research Resources2005–2006
  • AdministrativeNational Institute Of General Medical Sciences2005
  • Core--Clinical Trial Protocol Review And Monitoring SystemNational Cancer Institute2002
  • Glucuronidation (UGT) Of Sn38--Irinotecan ActivityNational Institute Of General Medical Sciences2000–2002
  • Optimal 06-Benzylguanine Dose For DNA Alkyltransferase DepletionNational Center For Research Resources2000–2002
  • Correlating UGT1A1 Genotype And Irinotecan Pharmacokinetics In Cancer PatientsNational Center For Research Resources2000–2002
  • Cancer And Leukemia Group B--Pet CommitteeNational Cancer Institute1998–2002
  • Phase I Trial Of ZD9331 As 30 MIN Infusion Daily For 5 DaysNational Center For Research Resources1997–2002
  • Phase I Clinical Trials Of Anticancer AgentsNational Cancer Institute1995–2002
  • Clinical And Experimental TherapeuticsNational Cancer Institute1996–2001
  • Core--Pharmacology FacilityNational Cancer Institute1992–2001
  • Cancer And Leukemia Group BNational Cancer Institute1995–1997
  • Phase I &Clinical Pharmacokinetics--Anticancer AgentsDivision Of Cancer Treatment1994–1995
  • Developmental TherapeuticsNational Cancer Institute1992–1995
  • Phase I &Clinical Pharmacokinetics - Anti-Cancer AgentsDivision Of Cancer Treatment1991–1993
  • Pharmacokinetics Of 4-Methyl-5-(2-Prazinyl)-1,2-Dithiol-3-Thione(Oltipraz)National Center For Research Resources1992
  • Phase I &Clinical Pharmacokinetics--Anti-Cancer AgentDivision Of Cancer Treatment1990–1991
  • Pharmacokinetic Analysis Of Continuous Intravenous Vinblastine InfusionNational Center For Research Resources1985–1987

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Cofinity PPO
    Coventry Health Care PPO Platinum
    Coventry Missouri - HMO/POS
    First Health PPO
    Great West PPO
    HealthLink PPO
    Multiplan PHCS PPO
    Multiplan PPO
    Sagamore Health Plus
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment